DE60042789D1 - Immobilisierte antigenbindende moleküle aus einer domäne - Google Patents

Immobilisierte antigenbindende moleküle aus einer domäne

Info

Publication number
DE60042789D1
DE60042789D1 DE60042789T DE60042789T DE60042789D1 DE 60042789 D1 DE60042789 D1 DE 60042789D1 DE 60042789 T DE60042789 T DE 60042789T DE 60042789 T DE60042789 T DE 60042789T DE 60042789 D1 DE60042789 D1 DE 60042789D1
Authority
DE
Germany
Prior art keywords
domain
binding molecules
immobilized antigen
binding fragments
devoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042789T
Other languages
English (en)
Inventor
Leo G J Frenken
Steven Daryl Grant
Ten Mark R Haaft
Der Logt Cornelis P Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BAC IP BV
Original Assignee
BAC IP BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BAC IP BV filed Critical BAC IP BV
Application granted granted Critical
Publication of DE60042789D1 publication Critical patent/DE60042789D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
DE60042789T 1999-11-29 2000-11-22 Immobilisierte antigenbindende moleküle aus einer domäne Expired - Lifetime DE60042789D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99309516 1999-11-29
PCT/EP2000/011656 WO2001044301A1 (en) 1999-11-29 2000-11-22 Immobilized single domain antigen-binding molecules

Publications (1)

Publication Number Publication Date
DE60042789D1 true DE60042789D1 (de) 2009-10-01

Family

ID=8241761

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042789T Expired - Lifetime DE60042789D1 (de) 1999-11-29 2000-11-22 Immobilisierte antigenbindende moleküle aus einer domäne

Country Status (10)

Country Link
US (1) US20160207986A1 (de)
EP (1) EP1233987B1 (de)
AT (1) ATE440111T1 (de)
AU (1) AU2161501A (de)
CY (1) CY1110517T1 (de)
DE (1) DE60042789D1 (de)
DK (1) DK1233987T3 (de)
ES (1) ES2331051T3 (de)
PT (1) PT1233987E (de)
WO (1) WO2001044301A1 (de)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE513854T1 (de) * 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1613273B1 (de) 2003-04-11 2012-06-13 MedImmune, LLC Rekombinante il-9-antikörper und ihre verwendung
CA2534661A1 (en) 2003-08-08 2005-02-17 Genenews Inc. Osteoarthritis biomarkers and uses thereof
CN101072794B (zh) * 2004-12-02 2012-07-04 贝克知产公司 亲和纯化方法
US7713695B2 (en) 2005-02-07 2010-05-11 Genenews, Inc. Mild osteoarthritis biomarkers and uses thereof
HUE045710T2 (hu) 2005-05-18 2020-01-28 Ablynx Nv Javított, alfa tumor nekrózis faktor elleni nanobodies
BRPI0609797B8 (pt) 2005-05-20 2021-05-25 Ablynx Nv nanocorpos melhorados para o tratamento de desordens mediadas por agregação
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
JP5237817B2 (ja) 2005-10-21 2013-07-17 ジーンニュース インコーポレーティッド バイオマーカー産物レベルを疾患に相関させるための方法および装置
BRPI0713426A2 (pt) 2006-06-14 2012-10-09 Macrogenics Inc métodos de tratar, diminuir a progressão, ou melhorar um ou mais sintomas de um distúrbio, e de prevenir ou retardar o inìcio de um distúrbio
TW201343676A (zh) 2006-08-28 2013-11-01 Kyowa Hakko Kirin Co Ltd 具拮抗性之人類ｌｉｇｈｔ專一性人類單株抗體
US8703136B2 (en) 2006-10-10 2014-04-22 Regenesance B.V. Complement inhibition for improved nerve regeneration
EP2115004A2 (de) 2006-12-19 2009-11-11 Ablynx N.V. Gegen gpcrs gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von mit gpcr in zusammenhang tehenden krankheiten und erkrankungen
WO2008074840A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
US20100129437A1 (en) 2007-03-23 2010-05-27 Bbb Holding B.V. Targeted intracellular delivery of antiviral agents
MX2020011303A (es) 2007-05-14 2021-12-17 Astrazeneca Ab Metodos para reducir niveles de eosinofilos.
US10214588B2 (en) 2007-07-03 2019-02-26 Ablynx N.V. Providing improved immunoglobulin sequences by mutating CDR and/or FR positions
JP2010533004A (ja) 2007-07-13 2010-10-21 バク アイピー ベスローテン フェンノートシャップ 哺乳動物ＩｇＧと結合する単一ドメイン抗原結合タンパク質
AU2008328779B2 (en) 2007-11-27 2014-06-05 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
CA2717015A1 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
EP2260058A2 (de) 2008-04-07 2010-12-15 Ablynx N.V. Variable einzeldomänen gegen notch-signalwege
AU2009237662A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
EP2403873A1 (de) 2009-03-05 2012-01-11 Ablynx N.V. Neue antigenbindende dimerkomplexe, verfahren zur herstellung/vermeidung und anwendungen davon
EP3828201A1 (de) 2009-04-30 2021-06-02 Ablynx N.V. Verfahren zur herstellung von domänenantikörpern
HUE051430T2 (hu) 2009-07-10 2021-03-01 Ablynx Nv Eljárás variábilis domének elõállítására
EP2473527B1 (de) 2009-09-03 2016-11-30 Ablynx N.V. Stabile formulierungen von polypeptiden und verwendungen davon
PT2491056T (pt) * 2009-10-22 2021-10-26 Univ Of Twente Vhh para aplicação na reparação de tecidos, regeneração de órgãos, substituição de órgãos e engenharia de tecidos
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
JP2013518853A (ja) 2010-02-05 2013-05-23 アブリンクス エン．ヴェー． 血清アルブミンと結合することが可能なペプチド並びにこれを含む化合物、構築物及びポリペプチド
CN102753148B (zh) 2010-02-11 2018-01-26 埃博灵克斯股份有限公司 用于制备气雾剂的方法和组合物
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
CN102939004B (zh) 2010-04-06 2015-09-23 阿格罗塞文公司 农用化学品的特异性输送
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
DK2632946T3 (en) 2010-10-29 2018-03-12 Ablynx Nv PROCEDURE FOR MANUFACTURING VARIABLE IMMUNGLOBULIN SINGLE DOMAINS
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
PT2691415T (pt) 2011-03-28 2018-10-19 Ablynx Nv Método para produção de formulações sólidas compreendendo domínios variáveis únicos de imunoglobulina
EP2707382B1 (de) 2011-05-09 2019-07-17 Ablynx NV Verfahren zur herstellung von variablen immunglobulin-einzeldomänen
WO2012163887A1 (en) 2011-05-27 2012-12-06 Ablynx Nv Inhibition of bone resorption with rankl binding peptides
EP2723772A1 (de) 2011-06-23 2014-04-30 Ablynx N.V. Gegen ige gerichtete variable immunglobulin-einzeldomänen
DK2747782T3 (en) 2011-09-23 2018-04-23 Ablynx Nv Long-term inhibition of interleukin-6-mediated signal transmission
US20150087517A1 (en) 2011-10-06 2015-03-26 Agrosavfe N.V. Manufacturing of specifically targeting microcapsules
CA2874309C (en) 2012-05-24 2021-06-15 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
DK3381943T3 (da) 2012-07-25 2022-05-16 Celldex Therapeutics Inc Anti-kit-antistoffer og anvendelser deraf
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
CA2899693C (en) 2013-01-30 2023-03-14 Vib Vzw Novel chimeric polypeptides for screening and drug discovery purposes
EP3590578A1 (de) 2013-02-05 2020-01-08 VIB vzw Muskarinische acetylcholinrezeptorbinder und verwendungen davon
AU2014229952B2 (en) 2013-03-15 2018-10-04 Vib Vzw Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases
WO2014191146A1 (en) 2013-04-29 2014-12-04 Agrosavfe N.V. Agrochemical compositions comprising antibodies binding to sphingolipids
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
WO2014197849A2 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
EP2883883A1 (de) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
JP6687525B2 (ja) 2014-01-30 2020-04-22 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ オピオイド受容体結合剤およびその使用
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
PT3148579T (pt) 2014-05-28 2021-03-11 Ludwig Inst For Cancer Res Ltd Anticorpos anti-gitr e métodos da sua utilização
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
CA2955554C (en) 2014-07-22 2022-07-05 Vib Vzw Methods to select for agents that stabilize protein complexes
US20180036442A1 (en) 2014-07-29 2018-02-08 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
DK3174559T3 (da) 2014-07-29 2022-12-05 Univ Brussel Vrije Radiomærkede antistoffragmenter til anvendelse inden for forebyggelsen og/eller behandlingen af cancer
CA2966548A1 (en) 2014-11-05 2016-05-12 Agrosavfe Nv Transgenic plant comprising a polynucleotide encoding a variable domain of heavy-chain antibody
CN107406497A (zh) 2014-12-19 2017-11-28 埃博灵克斯股份有限公司 半胱氨酸连接的纳米抗体二聚体
WO2016106221A1 (en) 2014-12-22 2016-06-30 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
CA2972604C (en) 2014-12-30 2023-07-04 Celgene Corporation Anti-cd47 antibodies and uses thereof
CN114504651A (zh) 2015-03-03 2022-05-17 科马布有限公司 抗体、用途和方法
WO2016149368A1 (en) 2015-03-17 2016-09-22 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
US10259882B2 (en) 2015-05-07 2019-04-16 Agenus Inc. Anti-OX40 antibodies
CA2986765A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
EP3325020B1 (de) 2015-07-17 2022-01-12 Vrije Universiteit Brussel Radioaktiv markierte antikörperfragmente zur verwendung bei der krebsbehandlung
KR20220131277A (ko) 2015-09-01 2022-09-27 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
BR112018010802A2 (pt) 2015-11-27 2018-11-27 Ablynx Nv polipeptídeos que inibem cd40l
WO2017182603A1 (en) 2016-04-22 2017-10-26 Université Libre de Bruxelles A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
WO2017182605A1 (en) 2016-04-22 2017-10-26 Université Libre de Bruxelles A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
CA3022697A1 (en) 2016-05-02 2017-11-09 Ablynx Nv Treatment of rsv infection
AU2017271588B2 (en) 2016-05-27 2022-01-20 Agenus Inc. Anti-TIM-3 antibodies and methods of use thereof
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
MA45602A (fr) 2016-07-08 2019-05-15 Staten Biotechnology B V Anticorps anti-apoc3 et leurs méthodes d'utilisation
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
SG10201912663YA (en) 2016-10-11 2020-03-30 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US11332521B2 (en) 2016-11-07 2022-05-17 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
KR102665596B1 (ko) 2016-11-16 2024-05-14 아블린쓰 엔.브이. Cd123 및 tcr 알파/베타에 결합할 수 있는 t 세포 동원 폴리펩티드
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
BR112019011582A2 (pt) 2016-12-07 2019-10-22 Agenus Inc. anticorpos e métodos de utilização dos mesmos
FI3551660T3 (fi) 2016-12-07 2023-12-11 Agenus Inc Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
JP7186401B2 (ja) 2017-02-28 2022-12-09 フエー・イー・ベー・フエー・ゼツト・ウエー タンパク質の経口送達のための手段及び方法
EP3596464B1 (de) * 2017-03-14 2021-08-11 NanoTag Biotechnologies GmbH Zieldetektion unter verwendung eines monovalenten antikörpers
SG11201908678XA (en) 2017-03-27 2019-10-30 Celgene Corp Methods and compositions for reduction of immunogenicity
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc anticorpos anti-cd137 e métodos de uso dos mesmos
EP3612648A1 (de) 2017-04-18 2020-02-26 Université Libre de Bruxelles Biomarker und targets für proliferative erkrankungen
AU2018255938A1 (en) 2017-04-21 2019-10-31 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
DK3618863T3 (da) 2017-05-01 2023-08-21 Agenus Inc Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
US11891451B2 (en) 2017-05-11 2024-02-06 Vib Vzw Glycosylation of variable immunoglobulin domains
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2018220225A1 (en) 2017-06-02 2018-12-06 Ablynx Nv Aggrecan binding immunoglobulins
TWI826376B (zh) 2017-06-02 2023-12-21 德商麥克專利有限公司 與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
BR112019025097A2 (pt) 2017-06-02 2020-07-28 Merck Patent Gmbh imunoglobulinas de ligação a mmp13
MX2019014400A (es) 2017-06-02 2020-02-10 Merck Patent Gmbh Inmunoglobulinas que se unen a adamts.
US11613588B2 (en) 2017-06-28 2023-03-28 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
WO2019016237A1 (en) 2017-07-19 2019-01-24 Vib Vzw AGENTS FOR CONNECTING TO SERUM ALBUMIN
EP3470436A1 (de) * 2017-10-11 2019-04-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Anti-igg-nanokörper
JP7039694B2 (ja) 2017-10-31 2022-03-22 スターテン・バイオテクノロジー・ベー・フェー 抗ａｐｏｃ３抗体およびその使用方法
EP3704160A1 (de) 2017-10-31 2020-09-09 VIB vzw Neuartige antigenbindende chimäre proteine und verfahren und verwendungen davon
WO2019155041A1 (en) 2018-02-12 2019-08-15 Vib Vzw Gβγ COMPLEX ANTIBODIES AND USES THEREOF
CA3092421A1 (en) 2018-03-01 2019-09-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
JP7390729B2 (ja) 2018-03-23 2023-12-04 ユニヴェルシテ リブル ドゥ ブリュッセル Ｗｎｔシグナル伝達アゴニスト分子
JP2021519093A (ja) 2018-03-27 2021-08-10 ユーエムシー ユトレヒト ホールディング ビー．ブイ． 微小血管血栓症の処置のための標的化血栓溶解
CA3098805A1 (en) 2018-05-10 2019-11-14 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
WO2019244961A1 (ja) * 2018-06-20 2019-12-26 Jsr株式会社 変異ｖｈｈ抗体を用いたアフィニティー担体
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof
MA53160A (fr) 2018-07-20 2021-05-26 Pf Medicament Récepteur pour vista
CA3113575A1 (en) 2018-10-03 2020-04-09 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
MA55080A (fr) 2019-02-26 2022-01-05 Inspirna Inc Anticorps anti-mertk à affinité élevée et utilisations associées
JP2022530549A (ja) 2019-04-29 2022-06-29 コンフォ セラピューティクス エヌ．ブイ． 膜貫通タンパク質、特にｇｐｃｒを伴う使用のためのスクリーニング方法及びアッセイ
WO2020221888A1 (en) 2019-04-30 2020-11-05 Vib Vzw Cystic fibrosis transmembrane conductance regulator stabilizing agents
WO2020239945A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
WO2020239934A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
PE20221151A1 (es) 2019-08-30 2022-07-18 Agenus Inc Anticuerpos anti-cd96 y sus metodos de uso
EP4048703A1 (de) 2019-10-21 2022-08-31 Vib Vzw Nanoscheibenspezifische antigenbindende chimäre proteine
MX2022005678A (es) 2019-11-11 2022-10-18 Ibi Ag Innovative Bio Insecticides Ltd Nanocuerpos para el control de insectos y usos de los mismos.
US20220411495A1 (en) 2019-11-27 2022-12-29 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
EP4077372A1 (de) 2019-12-20 2022-10-26 Vib Vzw Nanokörperaustauschchromatographie
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
JP2023514654A (ja) 2020-02-25 2023-04-06 ブイアイビー ブイゼットダブリュ ロイシンリッチリピートキナーゼ２のアロステリック調節因子
MX2022012376A (es) 2020-03-31 2023-02-15 Biotalys NV Polipeptidos antifungicos.
US20230279115A1 (en) 2020-04-22 2023-09-07 Mabwell (shanghai) Bioscience Co., Ltd. Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof
JPWO2021221050A1 (de) 2020-04-27 2021-11-04
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
EP4189060A1 (de) 2020-07-31 2023-06-07 Biotalys NV Expressionswirt
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
CA3196737A1 (en) 2020-09-24 2022-03-31 Massimiliano Mazzone Combination of p2y6 inhibitors and immune checkpoint inhibitors
KR20230074527A (ko) 2020-09-25 2023-05-30 아블린쓰 엔.브이. Il-13 및 ox40l을 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
US11897951B2 (en) 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
US20240076391A1 (en) 2020-12-24 2024-03-07 Oncurious Nv Human ccr8 binders
US20240052044A1 (en) 2020-12-24 2024-02-15 Vib Vzw Non-blocking human ccr8 binders
CA3206125A1 (en) 2020-12-24 2022-06-30 Vib Vzw Murine cross-reactive human ccr8 binders
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
CA3207548A1 (en) 2021-02-05 2022-08-11 Xavier Saelens Sarbecovirus binders
EP4294407A1 (de) 2021-02-17 2023-12-27 Vib Vzw Hemmung von slc4a4 bei der behandlung von krebs
WO2022175532A1 (en) 2021-02-19 2022-08-25 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
WO2022242892A1 (en) 2021-05-17 2022-11-24 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
EP4359421A1 (de) 2021-06-23 2024-05-01 Vib Vzw Mittel und verfahren zur auswahl spezifischer bindemittel
CN117580865A (zh) 2021-06-29 2024-02-20 山东先声生物制药有限公司 Cd16抗体及其应用
EP4377352A2 (de) 2021-07-30 2024-06-05 Vib Vzw Kationunabhängige mannose-6-phosphat-rezeptorbindemittel für gezielten proteinabbau
EP4378954A1 (de) 2021-07-30 2024-06-05 Shandong Simcere Biopharmaceutical Co., Ltd. Bispezifischer anti-pvrig/anti-tigit-antikörper und anwendung
WO2023057601A1 (en) 2021-10-06 2023-04-13 Biotalys NV Anti-fungal polypeptides
WO2023111266A1 (en) 2021-12-17 2023-06-22 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123
WO2023135198A1 (en) 2022-01-12 2023-07-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
WO2023148291A1 (en) 2022-02-02 2023-08-10 Biotalys NV Methods for genome editing
WO2023148397A1 (en) 2022-02-07 2023-08-10 Vib Vzw Engineered stabilizing aglycosylated fc-regions
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023213751A1 (en) 2022-05-02 2023-11-09 Umc Utrecht Holding B.V Single domain antibodies for the detection of plasmin-cleaved vwf
WO2023222825A1 (en) 2022-05-18 2023-11-23 Vib Vzw Sarbecovirus spike s2 subunit binders
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
WO2024105091A1 (en) 2022-11-15 2024-05-23 Imec Vzw Method and system for droplet manipulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927230D0 (en) * 1989-12-01 1990-01-31 Unilever Plc Reagents
GB8928501D0 (en) * 1989-12-18 1990-02-21 Unilever Plc Reagents
EP0584421A1 (de) * 1992-08-21 1994-03-02 Cécile Casterman Immunoglobuline ohne Leichtkette
EP1027439B1 (de) * 1997-10-27 2010-03-17 Bac Ip B.V. Multivalente antigenbindende proteine

Also Published As

Publication number Publication date
EP1233987B1 (de) 2009-08-19
EP1233987A1 (de) 2002-08-28
PT1233987E (pt) 2009-12-28
AU2161501A (en) 2001-06-25
DK1233987T3 (da) 2009-09-28
ATE440111T1 (de) 2009-09-15
ES2331051T3 (es) 2009-12-21
WO2001044301A1 (en) 2001-06-21
US20160207986A1 (en) 2016-07-21
CY1110517T1 (el) 2015-04-29

Similar Documents

Publication Publication Date Title
DE60042789D1 (de) Immobilisierte antigenbindende moleküle aus einer domäne
ATE412432T1 (de) Internalisierende erbb2 antikörper
HRP20000714B1 (en) NOVEL CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
DE3784638D1 (de) Verfahren zur bestimmung einer spezifisch bindefaehigen substanz.
BR9810654B1 (pt) mÉtodo de preparaÇço de um polipeptÍdeo, molÉculas de anticorpo e composiÇço.
DK1027439T3 (da) Multivalente antigenbindende proteiner
EA199800369A1 (ru) Способ переноса гена в клетки-мишени с помощью ретровируса
DE69731977D1 (de) Spezifische antikörper für dendritische zellen
IS2508B (is) Mótefni gegn ED-B hneppinu í fíbrónektíni, smíði þeirra og notkanir
DE69121849T2 (de) Bindung von Liganden an Gold
DK0979246T3 (da) Humane monoklonale antistoffer mod epidermal vækstfaktorreceptor
DE60138333D1 (de) Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen
DK0724456T3 (da) CD40-Antistoffer
ATE213507T1 (de) Methode zur bindung von material an das beta- amyloid-peptid
ATE264389T1 (de) Interleukin-5-spezifische rekombinante antikörper
AR009638A1 (es) Un procedimiento para la determinacion de un anticuerpo de la clase de inmunoglobulina m especifico contra antigenos
ATE323158T1 (de) Verwendung von vernetzten kristallen als neue form von immobilisierung von enzymen
DE59010825D1 (de) Monoklonale Antikörper (MAK) gegen tumorassoziierte Antigene, ihre Herstellung und Verwendung
ATE217086T1 (de) Herstellung von photoprotein konjugaten und verfahren zu ihrer verwendung
DE69633506D1 (de) Transepithelialer transport von molekularspezien
SE0004532D0 (sv) Use of mucin
ATE307201T1 (de) Srcr domäne-enthaltendes protein
ATE398142T1 (de) Antikörper gegen subersäure-crosslinker und ihre anwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition